Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/08/2005CA2567931A1 Salt forms of atorvastatin
12/08/2005CA2567929A1 3- {4- (pyridin-3-yl) phenyl} -5- (1h-1, 2, 3-triazol-1-ylmethyl) -1, 3-oxazolidin-2-ones as antibacterial agents
12/08/2005CA2567703A1 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
12/08/2005CA2567457A1 3- (4- (2-dihydroisoxazol-3-ylpyridin-5-yl) phenyl) -5-triazol-1-ylmethyloxazolidin-2-one derivaives as mao inhibitors for the treatment of bacterial infections
12/08/2005CA2567454A1 3-[4-(6-{4,5-dihydroisoxazol-3-yl}pyridin-3-yl)-3-phenyl]-5-(1h-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ones as antibacterial agents
12/08/2005CA2567437A1 Substituted triazoles as modulators of ppar and methods of their preparation
12/08/2005CA2567411A1 Transparent tissue-visualizing preparation
12/08/2005CA2567401A1 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
12/08/2005CA2567398A1 New use
12/08/2005CA2567397A1 Use of neboglamine (cr 2249) as an antipsychotic and neuroprotective
12/08/2005CA2567101A1 Estrogen modulation of ifn-gamma-mediated conditions and diseases
12/08/2005CA2567099A1 Induction of innate immunity by vitamin d3 and its analogs
12/08/2005CA2567056A1 Compositions and methods for enhanced mucosal delivery of parathyroid hormone
12/08/2005CA2566963A1 3-[4-{6-substituted alkanoyl pyridin-3-yl}-3-phenyl]-5-(1h-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ones as antibacterial agents
12/08/2005CA2566942A1 Androgen receptor modulators and method of treating disease using the same
12/08/2005CA2566863A1 Purine derivative
12/08/2005CA2566861A1 Methods and reagents for the treatment of immunoinflammatory disorders
12/08/2005CA2566798A1 Enteric solid oral dosage form of bisphosphonate containing a chelating agent
12/08/2005CA2566373A1 2-substituted 17-imino estrogen compounds for cytoprotection
12/08/2005CA2566362A1 Treating seizures using ice inhibitors
12/08/2005CA2566286A1 Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
12/08/2005CA2566202A1 Agent for preventing/ameliorating life style-related diseases containing turmeric essential oil component
12/08/2005CA2566156A1 Method for treating abnormal cell growth
12/08/2005CA2566154A1 Combination of atomoxetine and a 5t1a receptor agonist for treating adhd and other disorders
12/08/2005CA2566094A1 Cinnamide compound
12/08/2005CA2566051A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders
12/08/2005CA2566038A1 Anti-tubulin acting arylpyrrol, arylfulran and arylthiopene derivatives, method for the preparation and use thereof as an antimitotic
12/08/2005CA2565556A1 Polycationic antimicrobial therapeutic
12/08/2005CA2565486A1 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors
12/08/2005CA2565431A1 Antibiotic compound produced by fermentation with streptomyces sp.
12/08/2005CA2565321A1 Oculoselective drugs and prodrugs
12/08/2005CA2565263A1 2-styryl-4-oxazole-methanol-ethers and their use as tyrosine kinase inhibitors
12/08/2005CA2565257A1 Thioether derivatives, their manufacture and use as pharmaceutical agents
12/08/2005CA2565098A1 Treatment of neurodegenerative disease through intracranial delivery of sirna
12/08/2005CA2565095A1 Decreasing brain neuronal glutamate levels using alpha-keto branched chain amino acids
12/08/2005CA2565066A1 Therapeutic compounds
12/08/2005CA2565065A1 Therapeutic compounds: pyridine as scaffold
12/08/2005CA2564868A1 Methods for treating or preventing restenosis and other vascular proliferative disorders
12/08/2005CA2564668A1 Pyrrolidine derivatives
12/08/2005CA2564638A1 Aryl sulfonamide and sulfonyl compounds as modulators of ppar and methods of treating metabolic disorders
12/08/2005CA2564592A1 Compositions for improving breast health in women
12/08/2005CA2564139A1 Modulators of human g protein-coupled receptors for the treatment of hyperglycemia and related disorders
12/08/2005CA2564104A1 Pharmaceutical or cosmetic composition comprising mequinol and at least one depigmenting agent
12/08/2005CA2564100A1 Dermatological composition for the treatment of pigmentary disorders of the skin
12/08/2005CA2564077A1 Mequinol-based dermatological depigmenting composition
12/08/2005CA2563926A1 Transgenic models of alzheimer's disease and uses thereof in the treatment of a variety of neurodegenerative diseases
12/08/2005CA2563466A1 Anti-cytokine heterocyclic compounds
12/08/2005CA2563335A1 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
12/08/2005CA2562693A1 Reverse-turn mimetics and method relating thereto
12/08/2005CA2562565A1 Spot-on formulation useful for cosmetology and dermatology
12/08/2005CA2562035A1 Treatment of depressive disorders
12/08/2005CA2561672A1 Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
12/08/2005CA2509311A1 Fexofenadine polymorphs and process for the preparation thereof
12/08/2005CA2509265A1 Methods of delaying alzheimer's disease progression using a beta-amyloid precursor protein inhibitor and hmg coa reductase inhibitor
12/07/2005EP1602716A1 Selenium-enriched biomass, method of preparing thereof and probiotic and nutraceutic products including said biomass
12/07/2005EP1602704A1 Antioxidant, skin preparation for external use, cosmetic and food
12/07/2005EP1602669A1 Antibody against tumor specific antigen as target
12/07/2005EP1602668A1 Monoclonal antibodies specific to VEGF receptors and uses thereof
12/07/2005EP1602666A1 Novel protein and its dna
12/07/2005EP1602665A1 Physiologically active peptides and drugs containing the same
12/07/2005EP1602660A1 Aminophosphonic acid derivatives, addition salts thereof and s1p receptor modulators
12/07/2005EP1602659A1 Gm-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent
12/07/2005EP1602658A1 Tricyclic pyrazole derivatives as cannabinoid receptor antagonists
12/07/2005EP1602657A2 Substituted 9-alkyladenines
12/07/2005EP1602656A1 Pyrazole derivatives having affinity for cb1 and/or cb2 receptors
12/07/2005EP1602652A1 Adiponectin expression promoter
12/07/2005EP1602645A1 Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl
12/07/2005EP1602644A1 Pharmaceutical compositions containing sulphonic acid derivatives
12/07/2005EP1602404A1 Fine particles, method and device for preparation thereof, and agent for parenteral injection and method for production thereof
12/07/2005EP1602380A1 Preventive/remedy for diseases in upper digestive tract
12/07/2005EP1602377A1 Composition containing beta-glucan and constipation-relieving drug, immunopotentiator and skin moistening agent using the composition
12/07/2005EP1602376A1 Preventive/remedy for obesity
12/07/2005EP1602375A2 Administration of products of the 5-lipoxygenase pathway for treating microbial infections
12/07/2005EP1602374A1 Remedy for drug/substance dependence
12/07/2005EP1602373A1 Ocular hypotensive agent
12/07/2005EP1602372A1 Drug for improving prognosis for subarachnoid hemorrhage
12/07/2005EP1602371A2 Valproic acid and derivatives for the sensitisation of human cancer cells to increase efficacy in a combination therapy
12/07/2005EP1602370A2 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
12/07/2005EP1602369A2 Bupropion Metabolites and Methods of their Synthesis and Use
12/07/2005EP1602368A2 Cdc25 phosphatase inhibitors
12/07/2005EP1602367A1 Transdermal delivery system for treatment of cognitive disorders
12/07/2005EP1602362A1 Drug composition having active ingredient adhered at high concentration to spherical core
12/07/2005EP1602361A2 Antibiotic in the form of a water-soluble powder for veterinary and human use
12/07/2005EP1601789A2 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
12/07/2005EP1601767A2 USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF EIF-5A1
12/07/2005EP1601757A2 Cell-polymer fiber compositions and use thereof
12/07/2005EP1601680A2 Ferric organic compounds, uses thereof and methods of making same
12/07/2005EP1601678A2 Fused pyrrole compounds
12/07/2005EP1601675A1 Purin-6-one-derivatives
12/07/2005EP1601673A1 Novel fused heterocycles and uses thereof
12/07/2005EP1601672A1 Triazolo-pyridines as anti-inflammatory compounds
12/07/2005EP1601666A2 New neuropeptide y y5 receptor antagonists
12/07/2005EP1601665A2 Urea derivatives
12/07/2005EP1601663A1 Nitrate esters of phenylaminothiophenacetic acid derivatives
12/07/2005EP1601661A2 Compositions and methods for preventing and treating endotoxin-related diseases and conditions
12/07/2005EP1601658A1 Crystalline ammonium salts of rosuvastatin
12/07/2005EP1601656A1 Tetrahydroquinoline derivatives useful as serine protease inhibitors
12/07/2005EP1601652A2 Pyridinium salts, compounds and methods of use
12/07/2005EP1601649A2 A1 adenosine receptor antagonists
12/07/2005EP1601643A1 Arylcycloalkyl derivatives with branched side chains as ppar receptor modulators, method for their production and their use as medicaments
1 ... 4443 4444 4445 4446 4447 4448 4449 4450 4451 4452 4453 4454 4455 4456 4457 4458 4459 4460 4461 4462 4463 ... 7860